Superior vena cava syndrome (SVCS) is secondary to obstruction of venous flow from the superior vena cava to the right atrium. Endovascular stenting is particularly useful when severe or rapidly progressive disease requires urgent treatment. In suspected mediastinal malignancy, transcaval biopsy can be combined with endovenous stenting to provide diagnosis and treatment in a single procedure. Three patients were referred for investigation and treatment of SVCS over a 20 month period. Under fluoroscopic guidance Cook Medical transjugular biopsy sets (with 20-gauge QuickCore biopsy needles) were used and two or three core biopsy samples were obtained. Stents were utilised to treat SVC obstructions in two of three patients. Obtained samples were adequate for histological diagnosis. Diagnoses included small cell and small cell neuroendocrine carcinoma of the lung. No procedural complications were encountered. Importantly, no further invasive diagnostic procedures were required. This is a safe and effective alternative to obtain a histological diagnosis in malignant SVCS and in the appropriate clinical setting biopsy can be combined with SVC stenting in a single procedure.
Introduction
Superior vena cava syndrome (SVCS) consists of facial, neck and upper extremity swelling and oedema, facial plethora, dyspnoea and other symptoms relating to obstruction of venous flow from the superior vena cava to the right atrium. Distended venous collaterals are visible both clinically and on imaging. First described in 1757, extrinsic compression due to malignancy is the most common cause accounting for up to 95% of cases. [1] [2] [3] Treatment options for SVCS depend on clinical presentation and the underlying disease. In mild or slowly progressive SVCS, malignant causes may be treated with chemotherapy or radiotherapy. Endovascular stenting is particularly useful when severe or rapidly progressive disease requires urgent treatment. Surgical treatment can be effective but is associated with significant morbidity and mortality and is rarely used in malignant SVCS.
In suspected mediastinal malignancy, tissue diagnosis is usually obtained using CT guided biopsy, bronchoscopy or mediastinoscopy. The latter approaches are particularly relevant when no safe percutaneous access site exists. 4 In severe SVCS, elevated venous pressure and collateral vessels increase the risk of bleeding associated with these approaches. Laryngeal and cerebral oedema increases the risk associated with general anaesthesia. [5] [6] [7] Endovenous biopsy under local anaesthesia avoids these risks. In the appropriate clinical setting, biopsy can be combined with endovenous stenting to provide diagnosis and treatment in a single procedure.
We describe the indications and technique for transcaval core biopsy in three patients. In two of the patients, biopsy was followed by SVC stenting in a single procedure.
Methods
Three patients with malignant SVCS who underwent transcaval biopsy were identified over a 20 month period. Ethical approval was obtained from our institutions ethics review board and the need for patient consent waived.
Patients

Patient 1
An 82-year-old female presented with SVCS. Post-contrast CT revealed a large mediastinal mass. There was invasion of the SVC with an intraluminal component causing further luminal narrowing (Fig. 1a) . Transvenous biopsy was performed. No complication was observed (Fig. 1b,c) . SVC stenting was not performed as the SVCS was not rapidly progressive and was potentially treatable with chemotherapy or radiotherapy. The final histological diagnosis was small cell carcinoma (Fig. 1d) . The patient was subsequently treated with chemotherapy with an initial excellent clinical response.
Patient 2
A 51-year-old female presented with 3 days of headache, facial swelling and an inability to lie flat consistent with SVCS. Her past history was significant for a 40-pack-year smoking history and chronic obstructive pulmonary disease. Post contrast CT revealed a mediastinal mass superior to the level of the carina causing SVC obstruction and a large pericardial effusion (Fig. 2a,b) . Transvenous biopsy and SVC stenting was performed (Fig. 2c,d ). Two concentric 16 mm 9 60 mm Vena Stents were deployed. Immediate improvement in flow was demonstrated (Fig. 2e) . No complication was observed. Histology revealed small cell neuroendocrine lung carcinoma (Fig. 2f) .
The patient reported intermittent dyspnoea and tachycardia in the time immediately post stent insertion, however, these symptoms resolved and an otherwise excellent early clinical response of their symptoms was observed.
Patient 3
A 52-year-old male presented with several weeks of increasing shortness of breath, difficulty lying flat, facial congestion and distended jugular veins consistent with SVCS. His past history was significant for Hodgkin's Lymphoma. He was a current smoker at the time of presentation. Post-contrast CT demonstrated an irregular mediastinal mass causing significant narrowing of the luminal diameter of the superior vena cava. Urgent transvenous biopsy and endovenous stenting to relieve the SVC obstruction was performed (Fig. 3a) . After predilating the obstruction to 10 mm, a 14 mm 9 40 mm Zilver Vena self-expanding stent was deployed (Fig. 3b,c) . Post procedural cavogram revealed rapid flow through the stented segment with no further filling of collateral vessels (Fig. 3d) . No complication was observed. Histology revealed small cell carcinoma of the lung. The patient reported a good response to stenting.
Technical approach
Cross-sectional imaging was reviewed prior to the procedure identifying adjacent at risk anatomy to formulate a safe access point for biopsy.
Patients received intravenous sedation and analgesia with 1 mg midazolam and 25 µg fentanyl boluses. Patients monitoring was performed to ensure stable vital signs and oxygen saturation. Local anaesthetic (1% lignocaine) was infused at the site of planned puncture. Access to the femoral or internal jugular vein was obtained under ultrasound guidance, using a high frequency 5-12 MHz linear probe (Philips iU22 L12-5 Transducer) and a 9-French 10 cm vascular access sheath was introduced. Under fluoroscopic guidance, a 0.035 Amplatz J-wire (Boston Scientific, Natick, MA, USA) and 5-French angled catheter were advanced to the SVC obstruction. A cavogram allowed delineation of the anatomy, assessment of the degree of obstruction and accurate correlation with pre-procedural cross-sectional imaging. The catheter was exchanged for a Cook Medical transjugular biopsy set (Cook Medical, Bloomington, IN, USA). The angled sheathed metal cannula was directed towards the intended biopsy target and the 20-Gauge Quickcore biopsy needle deployed within the target (Fig. 2, 3) . Two or three 20 mm core biopsy samples were obtained and sent in formalin for histopathological assessment.
In patients 2 and 3, the stenotic lesion was then crossed with a hydrophilic wire (Terumo Glide Wire, Tokyo, Japan) and angled catheter. The stenosis was predilated with a 10 mm angioplasty balloon, and a 14 or 16 mm Cook Zilver Vena Stent (Cook Medical) deployed across the lesion. Stent length was selected to extend approximately 10 mm beyond the margins of the narrowed segment.
Post procedure cavogram was performed to assess for complication, patency and stent apposition with the SVC wall. If required, repeat dilatation was performed. Access site haemostasis was achieved with manual compression.
Results
Three patients were referred for investigation and/or treatment of SVCS. Table 1 (Figs 1-3) . Importantly, no further invasive diagnostic procedures were required. Diagnoses included small cell carcinoma and small cell neuroendocrine carcinoma of the lung.
Rapid improvement in SVCS after stenting was observed in patients 2 and 3 who were urgently stented due to the severity of their symptoms. Patient 1 was not stented prior to confirmation of a tissue diagnosis and was subsequently treated with chemotherapy with an initial excellent clinical response. This was followed by consolidation radiotherapy. Patient 2 was subsequently treated with chemotherapy and radiotherapy.
Follow-up morbidity and mortality related to metastatic burden. Patients 1 and 2 were alive and free from symptoms of SVCS at 4 months and 2 years, respectively. While functionally well, subsequent staging of patient 1 revealed progressive metastatic disease with new intracranial cerebral metastases. Patient 3 required repeat SVC stenting at 2 months due to enlarging nodal metastases and subsequently died at 8 months from progressive metastatic disease and complicating pulmonary aspergilloma.
Discussion
Mediastinoscopy is widely used for establishing a histological diagnosis in patients with mediastinal malignancy. 4 While morbidity and mortality of mediastinoscopy is low the procedure is relatively invasive, requires the use of general anaesthesia and risks are exacerbated in those with SVCS. 4 The risk of major bleeding requiring thoracotomy or sternotomy is increased in patients with elevated venous pressure associated with SVCS. 5, 6 Laryngeal oedema secondary to venous congestion complicates endotracheal intubation and increases the risk of airway bleeding. 7 Successful tranvenous biopsy of intraluminal tumour using endomyocardial biopsy forceps in malignant SVCS was first described in 1975. 8 Subsequent case reports have demonstrated the utility of this technique in diagnosing malignancy invading the SVC. 9, 10 Two case series with 8 and 10 patients, respectively, have demonstrated diagnostic accuracies of 75% and 100%, respectively, a figure comparable to CT-guided percutaneous biopsy. [11] [12] [13] [14] Our approach uses the Cook Transjugular Liver biopsy set. Advantages over biopsy forceps include improved sample size, and the ability to target lesions outside of the SVC. Familiarity with the device is an advantage for interventional radiologists who already perform transjugular liver biopsies.
The procedure is minimally invasive, avoids the need for further invasive diagnostic procedures, maximises patient comfort, has the potential for reduced hospital stay and cost and allows rapid progression to definitive treatment.
One limitation of this approach is the potential for unnecessary SVC stenting in potentially curable malignancy (e.g. lymphoma), particularly in young patients. This can be addressed by careful patient selection, and by the use of rapid histological analysis of frozen sections or touch preparation cytology during the procedure in selected patients.
Treatments for SVCS include medical management, radiotherapy, chemotherapy, endovenous stenting and surgical bypass. 3 Stenting is the accepted approach to urgently treat SVCS and should be offered in those with severe symptoms. It is reliable with efficacy of up to 95% and rapid with symptomatic relief being achieved within 72 hours. Medical management includes oral corticosteroids or diuretics to relieve laryngeal or cerebral oedema.
Radiotherapy and chemotherapy are commonly used to treat malignant causes of SVCS. Resolution of symptoms may be delayed or incomplete but there may be additional benefits associated with control of tumour growth. Both of these treatments require a histological diagnosis to be made prior to treatment. 16 Therapies may be combined, for example, medical therapy can be instituted on presentation, followed by semi-urgent transvenous biopsy and stenting, and chemotherapy or radiotherapy once histological diagnosis and tumour staging are complete.
Surgical management involves bypass using a polytetrafluroethylene (PTFE) tube or autologous vein graft. This is an invasive procedure with significant morbidity. It is most appropriate in patients with benign disease (e.g. mediastinal fibrosis) not responding to alternative treatments as it has been shown to be effective over a long period. 17 
Future directions
Transvenous core biopsy can be adapted to other sites, such as the juxtacaval retroperitoneum, which can be reached with existing transjugular biopsy sets in combination with other image guidance modalities like CT image fusion, cone beam CT, transabdominal and intravascular ultrasound. Using these modalities, there is potential to safely target smaller lesions or lesions that are not in direct contact with the vena cava. However, the potential for bleeding may be increased in lesions that are not adherent to the cava.
Maleux et al. report three cases of successful retroperitoneal tumoural mass biopsy via a transcaval approach. In these patients, percutaneous access was not possible due to intervening anatomy. Reconstructed cone beam CT (CBCT) at the time of the procedure improved confidence in lesional sampling and yielded adequate tissue samples for diagnosis of leiomyosarcoma, metastatic breast carcinoma and giant B-cell nonHodgkin Lymphoma respectively. 18 Intravascular ultrasound (IVUS) is already used in a range of transvenous renal and hepatic interventions. 19, 20 In conclusion, provided adequate tumour volume and anatomy transvenous core biopsy may provide a safe and effective alternative to mediastinoscopic, bronchoscopic or CT guided biopsy. Procedures can be performed via the transfemoral or transjugular route. In the setting of SVCS, biopsy can be combined with SVC stenting in a single procedure.
Informed consent
Informed consent for procedures was obtained from all individual participants included in the study.
